LingyiMed key facts
- Developer of biotechnology materials designed for pharmaceutical research and clinical application purposes.
- It has raised $29.4M; the latest was Early Stage VC in Dec 2025.
- Notable investors include HSG (Hong Kong), Shenzhen Yifeng Investment Management Enterprise, Hangzhou Capital, Holley Group, Jingjie Investment — 11 tracked in total.
- Status: Privately Held (backing).
Who backs LingyiMed
11+- ·The complete investor list: 11 names
- ·Watch LingyiMed: the Monday email on marks, rounds and moves
LingyiMed funding rounds
No funding rounds for LingyiMed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
LingyiMed investors
11 investors are on record for LingyiMed, including HSG (Hong Kong), Shenzhen Yifeng Investment Management Enterprise, Hangzhou Capital and Holley Group.
About LingyiMed
Developer of biotechnology materials designed for pharmaceutical research and clinical application purposes. The company operates a functional validation platform for rare disease animal models dedicated to innovated source, focusing on metabolic, CNS, ophthalmic, and other genetic rare diseases, enabling effective detection of rare disease in animals.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2021
- Employees
- 40
- Website
- lingyimed.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
LingyiMed doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.